EVOLUCARE AND ADCIS ANNOUNCE THE CREATION OF OPHTAI, A JOINT VENTURE DEDICATED TO ARTIFICIAL INTELLIGENCE FOR OPHTHALMOLOGY, AT THE NEXT FRENCH OPHTHALMOLOGY SOCIETY CONVENTION
On May 12, 2019, Evolucare, a medium-size enterprise largely renowned for its expertise in care organization and patient data management, and ADCIS, a company specializing in image analysis in a range of fields, including ophthalmology, chose the French Ophthalmology Society Convention (125th edition, May 11-14, 2019, Palais des Congrès de Paris) to ratify their alliance in the OphtAI joint venture (JV). These two players have worked together for many years on pioneering, ambitious research projects, and are now joining forces to occupy a solid position in the international ophthalmology market with a range of innovative services based on Artificial Intelligence (AI).
This collaboration will contribute to the development of a line of innovative products for early detection of retinal diseases and support to ophthalmology practice. By 2020, OphtAI will offer a range of over ten services based on AI to meet the needs of practitioners and patients.
The goal of this Joint Venture is to develop an entire range of software for the field of ophthalmology. The use of AI and Deep Learning in image processing and analysis is paving the way for mass screening of retinal pathologies in real time, with reduced costs and higher quality, to which patients will have easier, widespread access.
The first solution from this range is used for the semi-automated screening of Diabetic Retinopathy (DR). Coming in the form of an accessible online platform suitable for any kind of establishment, the CE-marked medical device will optimize practitioner productivity and make screening more secure.
